Roger's 1997 Short Picks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1997 Short Picks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Timoteo who wrote (6322)	10/30/1997 4:24:00 PM
From: Franco Battista	Read Replies (1) of 9285

One product companies in the drug sector are not unusual if they have the right product (one example Bayer with Aspirin). Also note that Vivus PR is very low key which does not help the stock price. Their competitors are raising quite a stink even though they have no proven product on the market. Pfizer has gone so far as saying that Viagra is their growth drug. Zonagen stock actually outperforms Vivus just on the hype. Both have yet to be approved by the FDA. This Pfizer hype is what is presently hurting the Vivus stock. Don't forget, Vivus made $100 miliion this year and production is quintupling next spring with foreign markets opening up at the same time. Hope this helps.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next